COMPANY

Ef Therapeutics LLC

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $1.06M (SBIR Phase II 5R44CA298522-02, continuation, notice Aug 28, 2026). NIH RePORTER 5R44CA298522-02 (Aug 28, 2026)
Evidence (1 event)
- Aug 28, 2026 · NIH RePORTER 5R44CA298522-02
  Organization: EF THERAPEUTICS CORP.; City/State: TAMPA, FL; Project number: 5R44CA298522-02; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-28; FY total cost (award amount): 1060745; Administering IC: National Cancer Institute; Project title: IntellipulseTM Platform Technology for Effective Delivery of Therapeutic Agents; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Aug 28, 2026 Grant Government grant — SBIR: $1.06M (annual award, as published), announced Aug 28, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Sep 3, 2025 Grant Government grant — SBIR: $984,830 (annual award, as published), announced Sep 3, 2025. Agency: NIH/NCI. Source: government award database. source ↗

Last 2 years.

Aug 28, 2026 Government grant — SBIR: $1.06M (annual award, as published), announced Aug 28, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Sep 3, 2025 Government grant — SBIR: $984,830 (annual award, as published), announced Sep 3, 2025. Agency: NIH/NCI. Source: government award database. source ↗